Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
7.41
0.00 (0.00%)
Sep 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.35 - 7.53
52 week 5.40 - 11.88
Open 7.43
Vol / Avg. 45,024.00/57,533.00
Mkt cap 321.54M
P/E     -
Div/yield     -
EPS -0.67
Shares 43.39M
Beta     -
Inst. own 33%
Nov 11, 2014
Q3 2014 Regulus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 3, 2014
Regulus Therapeutics Inc at FBR & Co Inaugural Healthcare Conference
Aug 13, 2014
Regulus Therapeutics Inc at Wedbush Securities Life Sciences Conference
Aug 6, 2014
Q2 2014 Regulus Therapeutics Inc Earnings Call
Aug 6, 2014
Q2 2014 Regulus Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -1626.77% -95.40%
Operating margin -1638.59% -96.82%
EBITD margin - -83.82%
Return on average assets -40.35% -16.48%
Return on average equity -55.08% -24.00%
Employees 76 -
CDP Score - -

Address

Suite 210, 3545 John Hopkins Court
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regulus Therapeutics Inc., is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012, the Company´┐Żs operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. Effective March 5, 2014, Sanofi SA of France acquired an undisclosed minority stake in Regulus Therapeutics Inc.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Kleanthis G. Xanthopoulos Ph.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Neil W. Gibson Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
David Szekeres Chief Business Officer, General Counsel, Corporate Secretary
Age: 40
Bio & Compensation  - Reuters
Paul C. Grint M.D. Chief Medical Officer
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 59
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Bruce L. A. Carter Ph.D. Independent Director
Bio & Compensation  - Reuters
Mark G. Foletta CPA Independent Director
Age: 53
Bio & Compensation  - Reuters